KR102806640B1 - 이종성 repRNA 면역접종을 위한 방법 및 조성물 - Google Patents

이종성 repRNA 면역접종을 위한 방법 및 조성물 Download PDF

Info

Publication number
KR102806640B1
KR102806640B1 KR1020207005743A KR20207005743A KR102806640B1 KR 102806640 B1 KR102806640 B1 KR 102806640B1 KR 1020207005743 A KR1020207005743 A KR 1020207005743A KR 20207005743 A KR20207005743 A KR 20207005743A KR 102806640 B1 KR102806640 B1 KR 102806640B1
Authority
KR
South Korea
Prior art keywords
composition
reprna
administered
ivt
antigenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207005743A
Other languages
English (en)
Korean (ko)
Other versions
KR20200037818A (ko
Inventor
로날드 보겔스
마린 반 데 노이트 코프쇼튼
대럴 제이. 어빈
론 웨이스
엘리 블랜턴 포터
마리앤 반데리아 멜로
타스쿠 키타다
Original Assignee
얀센 백신스 앤드 프리벤션 비.브이.
매사추세츠 인스티튜트 오브 테크놀로지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 백신스 앤드 프리벤션 비.브이., 매사추세츠 인스티튜트 오브 테크놀로지 filed Critical 얀센 백신스 앤드 프리벤션 비.브이.
Publication of KR20200037818A publication Critical patent/KR20200037818A/ko
Application granted granted Critical
Publication of KR102806640B1 publication Critical patent/KR102806640B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020207005743A 2017-07-28 2018-07-27 이종성 repRNA 면역접종을 위한 방법 및 조성물 Active KR102806640B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762538070P 2017-07-28 2017-07-28
US62/538,070 2017-07-28
US201762546259P 2017-08-16 2017-08-16
US62/546,259 2017-08-16
PCT/US2018/044075 WO2019023566A1 (en) 2017-07-28 2018-07-27 METHODS AND COMPOSITIONS FOR PROVIDING IMMUNIZATION AGAINST Heterologous ARNREP

Publications (2)

Publication Number Publication Date
KR20200037818A KR20200037818A (ko) 2020-04-09
KR102806640B1 true KR102806640B1 (ko) 2025-05-12

Family

ID=63407511

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207005743A Active KR102806640B1 (ko) 2017-07-28 2018-07-27 이종성 repRNA 면역접종을 위한 방법 및 조성물

Country Status (12)

Country Link
US (2) US11235051B2 (enExample)
EP (1) EP3658179B1 (enExample)
JP (1) JP7311489B2 (enExample)
KR (1) KR102806640B1 (enExample)
CN (1) CN111163799A (enExample)
AU (1) AU2018306614B2 (enExample)
BR (1) BR112020001052A2 (enExample)
CA (1) CA3071011A1 (enExample)
IL (1) IL272281B2 (enExample)
MA (1) MA49693A (enExample)
SG (1) SG11202000019RA (enExample)
WO (1) WO2019023566A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020121273A1 (en) * 2018-12-14 2020-06-18 Glaxosmithkline Biologicals Sa Heterologous prime boost vaccine compositions and methods
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
US11026894B2 (en) 2019-01-10 2021-06-08 Massachusetts Institute Of Technology Lipid nanoparticles and use thereof to deliver RNA polynucleotides
IL293051A (en) 2019-11-18 2022-07-01 Janssen Biotech Inc Vaccines based on mutant calr and jak2 and their uses
WO2021183564A1 (en) 2020-03-09 2021-09-16 Arcturus Therapeutics, Inc. Compositions and methods for inducing immune responses
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
JP2023537609A (ja) 2020-08-14 2023-09-04 アークトゥラス・セラピューティクス・インコーポレイテッド 脂質ナノ粒子を凍結乾燥する方法
US20220265813A1 (en) 2021-02-23 2022-08-25 Janssen Vaccines & Prevention B.V. Trimer Stabilizing HIV Envelope Protein Mutation
CA3173950A1 (en) 2021-03-22 2022-09-22 Tyson D. BOWEN Dna modifyng enzymes and active fragments and variants thereof and methods of use
CN115232824B (zh) * 2021-04-22 2023-09-26 中国人民解放军军事科学院军事医学研究院 一种基于1083骨架的预防狂犬病毒感染的疫苗
US20240400619A1 (en) * 2021-09-02 2024-12-05 Replicate Bioscience, Inc. Modified alphaviruses with heterologous nonstructural proteins
WO2023156505A1 (en) 2022-02-17 2023-08-24 Janssen Vaccines & Prevention B.V. Trimer stabilizing hiv envelope protein mutations r304v, n302m and t320l
CN116064597B (zh) * 2023-01-17 2024-04-26 北京大学 通过自主复制rna实现哺乳动物细胞中的定向进化和达尔文适应

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140271714A1 (en) * 2013-03-15 2014-09-18 Monika Simmons Induction of an immune response against dengue virus using the prime-boost approach
WO2016036971A1 (en) * 2014-09-03 2016-03-10 Bavarian Nordic A/S Methods and compositions for enhancing immune responses

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4255397A (en) 1996-09-06 1998-03-26 Trustees Of The University Of Pennsylvania, The Chimpanzee adenovirus vectors
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
AU2003271738C1 (en) 2002-04-25 2008-04-17 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
ATE447037T1 (de) 2002-04-25 2009-11-15 Crucell Holland Bv Mittel und verfahren zur herstellung von adenovirusvektoren
EP1687033A4 (en) * 2003-11-12 2008-06-11 Us Navy IMPROVEMENT OF VACCINE-INDUCED IMMUNE REACTIONS AND PROTECTION THROUGH HETEROLOGY REINFORCEMENT WITH ALPHAVIRUS REPLICON VACCINE
EP2163260B1 (en) 2004-01-23 2017-03-15 MSD Italia S.r.l. Chimpanzee adenovirus vaccine carriers
US20100143302A1 (en) 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
EP2146760B1 (en) 2007-04-30 2018-10-10 Medtronic MiniMed, Inc. Reservoir filling, bubble management, and infusion medium delivery systems and methods with same
EP3385387B1 (en) 2009-02-02 2021-08-25 GlaxoSmithKline Biologicals SA Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
WO2010085984A1 (en) 2009-02-02 2010-08-05 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
CA2766907A1 (en) 2009-07-06 2011-01-13 Novartis Ag Self replicating rna molecules and uses thereof
ES2563730T3 (es) * 2009-07-15 2016-03-16 Glaxosmithkline Biologicals S.A. Composiciones de proteína RSV F y procedimientos de fabricación de las mismas
FI4005592T3 (fi) 2010-07-06 2023-01-13 Virionin kaltaisia kuljetuspartikkeleita itsereplikoituville rna-molekyyleille
ES2676196T3 (es) 2010-12-14 2018-07-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Vacunas contra filovirus de adenovirus de serotipo 25 y serotipo 35
EP3632463A1 (en) * 2011-04-08 2020-04-08 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
WO2013006842A2 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
ES2753138T3 (es) * 2012-07-06 2020-04-07 Glaxosmithkline Biologicals Sa Complejos de proteínas de citomegalovirus
BE1023877B1 (fr) * 2015-05-21 2017-09-01 Glaxosmithkline Biologicals Sa Procédés et compositions pour l’induction d’une immunité protectrice contre une maladie et/ou une infection à filovirus

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140271714A1 (en) * 2013-03-15 2014-09-18 Monika Simmons Induction of an immune response against dengue virus using the prime-boost approach
WO2016036971A1 (en) * 2014-09-03 2016-03-10 Bavarian Nordic A/S Methods and compositions for enhancing immune responses

Also Published As

Publication number Publication date
US20220111033A1 (en) 2022-04-14
IL272281A (en) 2020-03-31
US20200230225A1 (en) 2020-07-23
US11235051B2 (en) 2022-02-01
IL272281B2 (en) 2023-04-01
EP3658179C0 (en) 2025-09-17
SG11202000019RA (en) 2020-02-27
AU2018306614A1 (en) 2020-01-30
JP2020528911A (ja) 2020-10-01
MA49693A (fr) 2020-06-03
AU2018306614B2 (en) 2024-08-29
KR20200037818A (ko) 2020-04-09
EP3658179A1 (en) 2020-06-03
EP3658179B1 (en) 2025-09-17
WO2019023566A1 (en) 2019-01-31
US11964007B2 (en) 2024-04-23
IL272281B (en) 2022-12-01
CN111163799A (zh) 2020-05-15
JP7311489B2 (ja) 2023-07-19
BR112020001052A2 (pt) 2020-09-08
CA3071011A1 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
KR102806640B1 (ko) 이종성 repRNA 면역접종을 위한 방법 및 조성물
AU2003297039B2 (en) Multi-antigenic alphavirus replicon particles and methods
EP2061508B1 (en) Alphavirus replicon particles matched to protein antigens as immunological adjuvants
EP2066346B1 (en) Alphavirus replicon particles encoding il-12 as immunological adjuvants
EP2416662B1 (en) Alphavirus replicon particles expressing trp2
EA043316B1 (ru) СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ГЕТЕРОЛОГИЧНЫХ репРНК ИММУНИЗАЦИЙ
AU2017276161B2 (en) Alphavirus Replicon Particles Expressing TRP2
EP4648781A1 (en) Recombinant modified sarna (vrp) for cancer vaccine

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200227

Patent event code: PA01051R01D

Comment text: International Patent Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20200304

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210603

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240215

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20241022

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

AMND Amendment
PX0901 Re-examination

Patent event code: PX09012R01I

Patent event date: 20250122

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20250213

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250508

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250508

End annual number: 3

Start annual number: 1

PG1601 Publication of registration